Last reviewed · How we verify

NCT04417712

Lifetech KONAR MFO Post-Market Clinical Follow-Up Study

Completed Last updated 15 April 2024
What this trial tests

trial testing KONAR-MF™ VSD Occluder in Ventricular Septal Defect in 40 participants. Completed in 30 June 2023.

Timeline
4 December 2019
Primary endpoint
30 March 2022
30 June 2023

Quick facts

Lead sponsorLifetech Scientific (Shenzhen) Co., Ltd.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date4 December 2019
Primary completion30 March 2022
Estimated completion30 June 2023
Sites4 locations across Italy, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Lifetech Scientific (Shenzhen) Co., Ltd. — full company profile →

Who can join

6 Months and older, any sex, with Ventricular Septal Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to collect real-world data on patient outcomes and evaluate the procedural success and performance of the Lifetech KONAR-MF™ VSD Occluder for patients with ventricular septal defect (VSD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ventricular Septal Defect

Currently open trials in the same condition.

Other Lifetech Scientific (Shenzhen) Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04417712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing